Related Experiment Video
Updated: Dec 6, 2025

12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
18.3K
Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies
Jessica N Williams1, Maria Dall'Era2, S Sam Lim3
1Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Arthritis Care & Research
|October 7, 2020
Summary
Non-White individuals with systemic lupus erythematosus (SLE) are underrepresented in clinical trials. Addressing societal and institutional barriers is crucial for increasing ancestral diversity in SLE research and optimizing treatments for all patients.
Area of Science:
- Rheumatology
- Clinical Trials
- Health Disparities
Background:
- Non-White populations exhibit higher systemic lupus erythematosus (SLE) prevalence but are underrepresented in clinical trials.
- Ancestry can influence drug efficacy and safety, necessitating diverse study populations for optimized SLE treatments.
- Barriers to clinical trial participation are disproportionately higher for non-White individuals.

